Background: Based on a prospectively planned interim analysis, the European study of interferon β-1b (IFNβ-1b) provided evidence that the treatment delays neurologic deterioration in patients with secondary progressive MS (SPMS). The authors analyzed all data collected until closure of the double-blind study to further scrutinize the consistency of the findings. Methods: The multicenter, double-blind, randomized, placebo-controlled trial treated patients for up to 36 months. The primary and all secondary endpoints of this study were evaluated using the data set at study termination, with a mean follow-up under double-blind conditions of 1054 ± 199 and 1068 ± 176 days for the placebo and IFNβ-1b group. Alternative and more demanding definitions of disease progression were explored. Confirmed progression was analyzed in subgroups according to baseline demographics and baseline indicators of disease activity. Results: Forty-eight of 358 placebo and 40 of 360 IFNβ-1b–allocated patients were lost to follow-up. Time to confirmed 1.0-point Expanded Disability Status Scale (EDSS) progression for patients receiving IFNβ-1b was delayed (p = 0.007). The proportion of patients with a confirmed 2.0-point EDSS progression was approximately 27% lower for the group treated with IFNβ-1b, both including and excluding EDSS data collected during relapses. The proportion of patients with either progression or relapses decreased by nearly 30% in patients treated with IFNβ-1b compared with placebo. Analysis of subgroups suggests that patients with higher prestudy disease activity (more than two relapses or EDSS progression by more than 1.0 point or both) seem to have a more pronounced treatment effect. Conclusion: Analysis of the data set at study termination including additional post hoc outcome measures is consistent with the original findings, thus supporting the conclusion that treatment with IFNβ-1b is effective in patients with SPMS fulfilling the inclusion criteria of this study.
[1]
J. Kurtzke.
Rating neurologic impairment in multiple sclerosis
,
1983,
Neurology.
[2]
G. Ebers,et al.
Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis
,
1998,
The Lancet.
[3]
Interferon beta-1b in secondary progressive multiple sclerosis--outline of the clinical trial.
,
1995,
Multiple sclerosis.
[4]
Ludwig Kappos,et al.
Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis
,
1998,
The Lancet.
[5]
D. Li,et al.
Randomized controlled trial of interferon-beta-1a in secondary progressive MS
,
2001,
Neurology.
[6]
Jeffrey A. Cohen,et al.
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.
,
1995,
Neurology.
[7]
G. Barker,et al.
Effect of interferon‐β1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: Results of a European multicenter, randomized, double‐blind, placebo‐controlled trial
,
1999
.
[8]
Randomized controlled trial of interferon- beta-1a in secondary progressive MS
,
2001,
Neurology.